Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
Holding VRTX?
Track your performance easily
VRTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$341.90 - $510.64
Previous Close$471.12
Volume1.35M
Average Volume (3M)1.06M
Market Cap
$121.60B
Enterprise Value$116.74B
Total Cash (Recent Filing)$5.80B
Total Debt (Recent Filing)$933.40M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Nov 04, 2024EPS Estimate
$4.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding258,102,203
10 Day Avg. Volume944,594
30 Day Avg. Volume1,064,620
Standard Deviation0.07
R-Squared0.08
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)8.23
Price to Sales (P/S)11.88
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.29
Enterprise Value/Gross Profit13.56
Enterprise Value/Ebitda-154.47
Forecast
1Y Price Target
$515.11Price Target Upside9.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
Vertex Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Cystic Fibrosis TreatmentVRTX's CFTR modulators have transformed the treatment of cystic fibrosis (CF), but only for patients with genetic mutations that are amenable.
Non-Opioid Pain MedicationsNon-opioid pain medications are desperately needed by physicians, and there is a significant drive to use these medications if they are made available.
Trial Strategy And SuccessMechanism of action is noted as more direct, providing confidence in the trial's success.
Bears Say
Financial PerformanceVRTX reported $2.65B (-1% q/q; +6% y/y) in 2Q24 total WW revenue, just below the $2.71B estimate.
Market CompetitionVertex's high reliance on cystic fibrosis products poses a risk due to increased competition, impacting revenue and growth prospects.
Product EfficacySuzetrigine appeared inferior to HB/APAP on SPID48 in the monotherapy setting, particularly on the time to onset of action in the bunionectomy setting.
---
Ownership Overview
0.18% Insiders
35.02% Mutual Funds
2.37% Other Institutional Investors
39.22% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $341.90 and its highest was $510.63 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Currently, no data Available
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is Nov 04, 2024 which is 47 days ago.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Aug 01, 2024. The company reported -$12.83 earnings per share for the quarter, missing the consensus estimate of -$11.626 by -$1.204.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is $4.08.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 258,102,200 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of -$12.83 in its last earnings report, missing expectations of -$11.626. Following the earnings report the stock price went down -2.238%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Among the largest hedge funds holding Vertex Pharmaceuticals’s share is Antipodes Partners Ltd. It holds Vertex Pharmaceuticals’s shares valued at 60M.
---
Vertex Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$515.11 (9.34% Upside)
$515.11 (9.34% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 96%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 209.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.56%
12-Months-Change
Fundamentals
Return on Equity
-3.24%
Trailing 12-Months
Asset Growth
-1.07%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
---
VRTX Company Deck
---
VRTX Earnings Call
Q2 2024
0:00 / 0:00
---
VRTX Revenue Breakdown
90.63% TRIKAFTA/KAFTRIO
4.82% KALYDECO
3.30% ORKAMBI
1.25% SYMDEKO/SYMKEVI
---
VRTX Stock 12 Month Forecast
Average Price Target
$515.11
▲(9.34% Upside)
Technical Analysis
Best Analysts Covering VRTX
1 Year
1 Year Success Rate
12/13 ratings generated profit
1 Year Average Return
+25.17%
reiterated a buy rating 2 months ago
Copying Olivia Brayer's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +25.17% per trade.
---